Allogene Therapeutics, Inc. financial data

Symbol
ALLO on Nasdaq
Location
210 East Grand Avenue, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 882 % -24.8%
Debt-to-equity 34 % +29.6%
Return On Equity -57.8 % +0.48%
Return On Assets -43.1 % +6.26%
Operating Margin -1.24M % -260%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 225M shares +7.18%
Common Stock, Shares, Outstanding 223M shares +6.52%
Entity Public Float 354M USD -36.4%
Common Stock, Value, Issued 223K USD +6.19%
Weighted Average Number of Shares Outstanding, Basic 222M shares +6.14%
Weighted Average Number of Shares Outstanding, Diluted 222M shares +6.14%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 166M USD -17.6%
General and Administrative Expense 58.5M USD -12.5%
Operating Income (Loss) -227M USD +23.6%
Nonoperating Income (Expense) 15.8M USD +10%
Net Income (Loss) Attributable to Parent -212M USD +25.2%
Earnings Per Share, Basic 0 USD/shares +37%
Earnings Per Share, Diluted 0 USD/shares +37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.8M USD -26.2%
Cash, Cash Equivalents, and Short-term Investments 277M USD -31.3%
Assets, Current 261M USD -14.4%
Property, Plant and Equipment, Net 75.9M USD -14.7%
Operating Lease, Right-of-Use Asset 40.9M USD -11.6%
Other Assets, Noncurrent 3.51M USD -29.3%
Assets 440M USD -25.4%
Accounts Payable, Current 3.7M USD -32.8%
Employee-related Liabilities, Current 12.1M USD -4.1%
Contract with Customer, Liability, Current 86K USD 0%
Liabilities, Current 31.8M USD -2.27%
Operating Lease, Liability, Noncurrent 77.1M USD -9.4%
Other Liabilities, Noncurrent 15.5M USD +102%
Liabilities 124M USD -0.74%
Accumulated Other Comprehensive Income (Loss), Net of Tax 235K USD +49.7%
Retained Earnings (Accumulated Deficit) -1.97B USD -12%
Stockholders' Equity Attributable to Parent 315M USD -32%
Liabilities and Equity 440M USD -25.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52.9M USD +5.31%
Net Cash Provided by (Used in) Financing Activities 14M USD +748%
Net Cash Provided by (Used in) Investing Activities 6.18M USD -72.1%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 223M shares +6.52%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -32.8M USD -2.02%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 48.1M USD -21.8%
Deferred Tax Assets, Valuation Allowance 445M USD +11.3%
Deferred Tax Assets, Gross 456M USD +9.14%
Operating Lease, Liability 85.1M USD -7.98%
Depreciation 3.56M USD +1.37%
Payments to Acquire Property, Plant, and Equipment 99K USD +1138%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -212M USD +24.5%
Lessee, Operating Lease, Liability, to be Paid 109M USD -10.5%
Property, Plant and Equipment, Gross 145M USD -2.12%
Operating Lease, Liability, Current 8.01M USD +8.38%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.6M USD +3.42%
Lessee, Operating Lease, Liability, to be Paid, Year One 13.2M USD +1.89%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 24.3M USD -18.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 14.1M USD +3.42%
Deferred Tax Assets, Operating Loss Carryforwards 244M USD +15.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 22M USD +16.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 15.5M USD +9.97%
Operating Lease, Payments 3.1M USD +3.33%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.1M USD -12.8%
Share-based Payment Arrangement, Expense 42.4M USD -21.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%